Early Discount Makes Rejection of Astellas’ Xtandi Too Difficult For NICE
This article was originally published in The Pink Sheet Daily
Executive Summary
By offering an early discount and providing clear clinical effectiveness evidence, Astellas Pharma has propelled its prostate cancer drug Xtandi through U.K.’s NICE.
You may also be interested in...
Europe’s CHMP Okays Xtandi, Erivedge And Spedra, But Rejects Xeljanz
Two new cancer therapies – Astellas’ prostate cancer drug Xtandi and Roche’s basal cell carcinoma drug Erivedge – have been cleared for European approval by the CHMP scientific advisory panel. It also backed Vivus’ erectile dysfunction therapy Spedra and Avanir’s emotional outburst therapy, Nuedextra, but turned down Pfizer’s JAK inhibitor Xeljanz.
Xtandi Gets Speedy Approval; Medivation/Astellas Already Prepped For Launch
FDA announced approval of Medivation/Astellas’ androgen receptor inhibitor Xtandi (enzalutamide) a little over three months after the NDA for metastatic castration-resistant prostate cancer was submitted, and the sponsors expect to begin promotions shortly after the U.S. Labor Day holiday.
NICE Price: Zytiga On Track In England After Discount
Janssen’s decision to offer the NHS a discount for its oral prostate cancer treatment Zytiga appears to have paid off, giving the drug a boost and head start over potential rivals in the EU.